MedTrace Logo

IntraRenal HEmoDynamics to IntegraTE CA-AKI Risk and Monitor NephroprotectiIoN by ImpElla Support.

NCT06599424 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2024-09-19

No results posted yet for this study

Summary

the hypothesis is that elevation of the intrarenal resistive index (RI) characterizes patients at elevated risk for subsequent CA-AKI and integrates items of the Mehran AKI risk score into a single, readily obtainable parameter. Impella-mediated nephroprotection confers to reduction of elevated RI by restoration of intrarenal venous flow profile.

Conditions

Interventions

OTHER

Observational

Observational

Sponsors & Collaborators

  • German Heart Center

    collaborator OTHER

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Principal Investigators

  • Malte Kelm, Prof. · Division of Cardiology, Pulmonary Disease and Vascular Medicine

  • Amin Polzin, Prof. · Division of Cardiology, Pulmonary Disease and Vascular Medicine

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-10-31
Completion
2025-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06599424 on ClinicalTrials.gov